Clinical trials: SARS
Health Behavior, Health Care Utilization
RADx-UP Phase 3D (Oregon Saludable: Juntos Podemos)
The ongoing Oregon Saludable: Juntos Podemos (OSJP, Healthy Oregon: Together We Can) project was developed to directly address the COVID-19 related health disparities among Latinx communities through community engagement funded…
- Conditions
- Health Behavior, Health Care Utilization, Vaccine Hesitancy
- Trial name
- NCT05910879
- Testing
- Self-Affirmation Implementation Intentions (SAII) Intervention, Promotores de Salud (Health Education)
- Where
- United States
- Volunteers
- 625 people
- Sponsor
- University of Oregon
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
The study is a randomized, double-blind, positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E compared with mRNA-1273 (the mRNA COVID-19 vaccine from Moderna) in population aged…
- Trial name
- NCT05345873
- Testing
- SCTV01E, mRNA-1273
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID
Convalescent Plasma in the Treatment of COVID 19
The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID, Coronavirus
- Trial name
- NCT04343261
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Trinity Health Of New England
SAR-CoV-2, Cellular Immune Response
Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection
Twelve months after the first SARS-CoV-2 cases in Wuhan, the FDA approved the first COVID-19 vaccine (Pfizer-BioNTech). Early studies on healthcare workers showed that antibody levels, especially against the Spike protein…
- Conditions
- SAR-CoV-2, Cellular Immune Response, Antibody Response
- Trial name
- BioVAC-immunit (NCT07049497)
- Testing
- Evaluation of the T cell response in terms of IFN-γ measured by ELISpot
- Where
- Italy
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
COVID-19
SARS-CoV-2 Infection Among Healthcare Workers
At present, COVID-19 vaccine is considered as the safest, economic and effective measure to prevent and control COVID-19. Adaptive immunity, including humoral immunity and cellular immunity, plays a role in anti-viral responses.
- Trial name
- NCT05680896
- Testing
- inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contaminated Medical or Biological Substances
PERSONAL PROTECTION EQUIPMENT AND SARS-CoV-2 CONTAMINATION
Transmission of SARS-CoV-2 occurs through common routes, aerosols and medical procedure. Personal protective equipment (PPE) reduces the risk of contamination.
- Trial name
- NCT05008627
- Where
- Israel
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bnai Zion Medical Center
Healthy Volunteers
Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants
This study will assess how safe ABBV-990 is and how ABBV-990 moves through the body of adult healthy participants. Adverse Events will be assessed.
- Trial name
- NCT05475821
- Testing
- ABBV-990
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
COVID-19, Fatigue
Differential Diagnosis of Persistent COVID-19 by Artificial Intelligence
The pandemic caused by SARS-CoV-2 infection has resulted, in addition to the well-known acute symptoms, in the emergence of persistent, diffuse and heterogeneous symptoms referred to as persistent COVID.
- Conditions
- COVID-19, Fatigue, Distress Respiratory Syndrome, Cognitive Dysfunction
- Trial name
- DICOPERIA (NCT05629793)
- Testing
- Experimental tests
- Where
- 7 sites in Spain
- Volunteers
- 136 people
- Sponsor
- Fundacin Biomedica Galicia Sur
COVID
Cardiac Imaging in SARS-CoV-2 (COVID-19)
One-in-four patients with COVID-19 pneumonia develop life-threatening heart problems. Through cardiovascular imaging and biomarkers analyses this study aims to evaluate whether COVID-19 infection results in heart injury.
- Trial name
- CISCO-19 (NCT04403607)
- Where
- 3 sites in United Kingdom
- Volunteers
- 180 people
- Sponsor
- NHS Greater Glasgow and Clyde
Prevention of COVID19
Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)
This study aims to evaluate the immunogenicity of Moderna mRNA-1273 vaccine in volunteers aged 65 years or more compared to volunteers aged 18-45 years, over 24 months duration.
- Trial name
- CoviCompareM (NCT04748471)
- Testing
- mRNA-1273
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Biological Availability, Healthy Participants
A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants
Medicines that may have different names or be made in different ways but have the same effect on the body are called bioequivalent.
- Trial name
- NCT06397144
- Testing
- Paxlovid, Nirmatrelvir/ritonavir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Post-COVID19
Automatic Oxygen Titration in Patients After SARS-CoV-2 Infection
With the progression of the SARS-CoV-2 pandemic there's an increasing number of patients recovering from COVID19. Some of these patients still experience hypoxemia and therefore are still in need of a long-term oxygen therapy…
- Trial name
- NCT04849598
- Testing
- Oxygen therapy
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Schön Klinik Berchtesgadener Land
SARS-CoV2 Infection
Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19)
Primary purpose: To investigate the effect of propolis, a food supplement product, on healing parameters in patients with COVID 19. Secondary purpose: To provide a new supportive treatment in Covid 19 treatment.
- Trial name
- NCT04916821
- Testing
- propolis
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Trabzon Kanuni Education and Research Hospital
SARS
Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study
This is a multi-center, randomized, double-blinded, placebo-controlled, outpatient study. Recombinant deltaTM S Protein Severe Acute Respiratory Syndrome (SARS) Vaccine With and Without Aluminum Hydroxide Adjuvant (Provided…
- Trial name
- NCT01376765
- Testing
- Aluminum hydroxide adjuvant (Alhydrogel®), Recombinant S protein SARS vaccine
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid-19, Cardiovascular Risk Factor
Telemedicine in Outpatient Covid-19 Patients
Covid-19, a commonly severe respiratory tract infection caused by the SARS-CoV2 Coronavirus, poses an increasing threat to individual health and health care systems.
- Trial name
- COVID-SMART (NCT04471636)
- Testing
- Withings ScanWatch
- Where
- Germany
- Volunteers
- 607 people
- Sponsor
- Ludwig-Maximilians - University of Munich
COVID-19
Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine
This is a randomized, observer-blind, placebo-controlled study, for evaluation of safety and immunogenicity of heterologous prime-boost immunization of recombinant COVID-19 vaccine (adenovirus type-5 vector) and RBD-based protein…
- Trial name
- NCT04833101
- Testing
- recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against COVID-19, trivalent split influenza vaccine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
SARS-CoV-2, Influenza A
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag Ultra test in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and LumiraDx SARS-CoV-2 \& Flu A/B…
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, COVID-19
- Trial name
- PURSUE (NCT05728970)
- Testing
- LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
- Where
- 10 sites in United States
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Post Acute Sequelae of SARS CoV 2 Infection, Obstructive Sleep Apnea
Predictors of Post-COVID-19 Clinical and Cognitive Consequences
The CDC describes Post-acute sequelae of SARS-COV-2 infection (PASC) for the wide range of physical and mental health consequences experienced by some patients.
- Trial name
- SCLC (NCT06291870)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Covid19, Pregnancy Related
Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection
This is a multi-center prospective study that aims to investigate the clinical and immunologic impact of SARS-CoV-2 infection in pregnant women and neonates.
- Conditions
- Covid19, Pregnancy Related, Neonatal Infection
- Trial name
- NCT04362956
- Where
- Argentina
- Volunteers
- 114 people
- Sponsor
- Fundacion Infant
COVID-19
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted…
- Trial name
- NCT04452942
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- EicOsis Human Health Inc.